Deoxycholic Acid Obesity Drugs Market Report 2026

The deoxycholic acid obesity drugs market size has grown rapidly in recent years. It will grow from $0.5 billion in 2025 to $0.57 billion in 2026 at a compound annual growth rate (CAGR) of 14.4%. The growth in the historic period can be attributed to increasing consumer awareness of aesthetic treatments, expansion of medical aesthetics clinics, rising acceptance of minimally invasive procedures, availability of approved deoxycholic acid formulations, growth in disposable income.

The deoxycholic acid obesity drugs market size is expected to see rapid growth in the next few years. It will grow to $0.97 billion in 2030 at a compound annual growth rate (CAGR) of 14.1%. The growth in the forecast period can be attributed to increasing demand for personalized aesthetic treatments, expansion of combination aesthetic protocols, rising focus on body contouring procedures, growing investments in aesthetic drug innovation, increasing penetration in emerging markets. Major trends in the forecast period include increasing adoption of non-surgical fat reduction procedures, rising demand for injectable aesthetic treatments, growing development of combination lipolytic therapies, expansion of clinic-based body contouring services, enhanced focus on patient-specific aesthetic outcomes.

The increasing obesity rates are expected to drive the growth of the deoxycholic acid obesity drug market in the coming years. Obesity rates indicate the proportion of a population categorized as overweight or obese based on body mass index (BMI). The rise in obesity rates is largely due to unhealthy dietary patterns, including high consumption of processed foods and sugary beverages, which lead to excess calorie storage as body fat. Deoxycholic acid obesity drugs aid in lowering obesity rates by breaking down and removing surplus fat cells, resulting in targeted fat reduction and enhanced body contour. For example, in May 2025, according to the Office for Health Improvement and Disparities, a UK government agency, an estimated 64.5% of adults aged 18 and above in England were overweight or living with obesity from 2023 to 2024, up from 64% in 2022 to 2023. Consequently, the rising obesity rates are fueling the growth of the deoxycholic acid obesity drug market.

The increasing demand for non-surgical body contouring solutions is expected to drive the growth of the deoxycholic acid obesity drug market in the coming years. Non-surgical body contouring solutions refer to non-invasive or minimally invasive procedures that utilize technologies such as cryolipolysis, ultrasound, radiofrequency, or lasers to reduce fat, tighten skin, and reshape the body without surgery or downtime. The demand for non-surgical body contouring is growing as consumers seek safer, minimally invasive alternatives to traditional cosmetic surgery that offer effective fat reduction and skin tightening with minimal pain, lower risk, and little to no recovery time. Deoxycholic acid obesity drugs assist in non-surgical body contouring by breaking down and eliminating localized fat cells when injected into targeted areas, resulting in a reduction of stubborn fat deposits and improved body shape without the need for invasive surgery. For example, in June 2024, according to the International Society of Aesthetic Plastic Surgery, a US-based professional organization, botulinum toxin remained the leading non-surgical procedure for all genders and age groups in 2023, with plastic surgeons performing 8.8 million treatments globally, while hyaluronic acid procedures increased 29% to reach 5.5 million. Therefore, the growing demand for non-surgical body contouring solutions is driving the expansion of the deoxycholic acid obesity drug market.

Major companies operating in the deoxycholic acid obesity drug market are concentrating on developing advanced products, such as injectable deoxycholic acid obesity drugs, to improve treatment effectiveness and enhance patient outcomes. Injectable deoxycholic acid obesity drugs utilize deoxycholic acid, a compound that breaks down fat cells, and are administered via injection to specifically target and reduce fat in particular areas. For example, in March 2024, LG Chem Ltd., a South Korea-based chemicals company, launched Bellacholine for the reduction of submental fat. This nonsurgical injection is designed to reduce moderate to severe submental fat (double chin) by safely destroying fat cells with deoxycholic acid. It provides benefits such as body-compatible pH, minimal sedimentation, and support for skin elasticity through collagen synthesis.

Major companies operating in the deoxycholic acid obesity drugs market are AbbVie Inc., Cipla Ltd., Glenmark Life Sciences Limited, Curia Global Inc., Daewoong Pharmaceutical Co. Ltd., Actylis, ICE Pharma, Cayman Chemical Company, Nacalai Tesque Inc., Sichuan Huiyu Pharmaceutical, Conscientia Industrial, Manus Aktteva Biopharma LLP, Jeevan Chemicals & Pharmaceuticals, Anhui Chem-Bright Bioengineering Co. Ltd., GlpBio Technology LLC, Legere Pharmaceuticals, Otto Chemie Pvt. Ltd., BOC Sciences, Guangzhou Green Cross Pharmaceutical, Prodotti Chimici e Alimentari S.P.A.

North America was the largest region in the deoxycholic acid obesity drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the deoxycholic acid obesity drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the deoxycholic acid obesity drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the deoxycholic acid obesity drugs market by increasing costs of imported active pharmaceutical ingredients, formulation excipients, sterile packaging materials, and medical-grade syringes. North America and Europe are most affected due to dependence on imported pharmaceutical inputs, while Asia-Pacific faces higher costs for formulation and distribution components. These tariffs are contributing to higher treatment costs and pricing pressure in aesthetic clinics. However, they are also driving local formulation manufacturing, regional supply chain optimization, and increased investment in domestic aesthetic pharmaceutical production.

The deoxycholic acid obesity drugs market research report is one of a series of new reports that provides deoxycholic acid obesity drugs market statistics, including deoxycholic acid obesity drugs industry global market size, regional shares, competitors with a deoxycholic acid obesity drugs market share, detailed deoxycholic acid obesity drugs market segments, market trends and opportunities, and any further data you may need to thrive in the deoxycholic acid obesity drugs industry. This deoxycholic acid obesity drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Deoxycholic acid obesity drugs are pharmaceutical formulations containing deoxycholic acid, a naturally occurring bile acid, developed to break down and remove localized fat deposits. They are primarily used in non-surgical fat reduction treatments, focusing on areas such as the chin, abdomen, and other stubborn fat regions.

The primary types of deoxycholic acid obesity drugs include ATX-101 (deoxycholic acid injection, also known as Kybella or Belkyra), experimental or compounded deoxycholic acid formulations, combination therapies, and oral deoxycholic acid products. ATX-101 (Deoxycholic Acid Injection, or Kybella, or Belkyra) refers to the commercially approved injectable forms of deoxycholic acid used for targeted fat reduction. These are available in various formulations, including injectable and topical options, and are distributed through multiple channels, such as direct sales, retail pharmacies, and online pharmacies. These drugs are used for a range of applications, including submental fat reduction, abdominal fat reduction, thighs, arms, and flanks, lipomas, localized fat, and cellulite management, and are primarily utilized by different end-users, including aesthetic clinics, dermatology clinics, plastic surgery centers, hospitals, and administration.

The deoxycholic acid obesity drugs market consists of sales of injection lipolysis with bile acid derivatives, investigational and preclinical agents. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.